Daratumumab

Monoclonal antibody

Also known as JNJ-54767414

Biosimilars tracked: CT-P44

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:AL Amyloidosis · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of relapsed or refractory multiple myeloma
Product first approved 2017PMDA
EU
  • Multiple Myeloma Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1). in as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. Smouldering multiple myeloma Darzalex as monotherapy is indicated for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma. Light chain (AL) amyloidosis Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. Darzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (50)
AL Amyloidosis
NCT06022939 · SWOG Cancer Research Network
2024-07-01 – 2030-10-29 · AL Amyloidosis
What this study did
NCT05776940 · Air Force Military Medical University, China
2023-03-31 – 2026-03-31 · Immunoglobulin Light-chain Amyloidosis
What this study did
Multiple Myeloma
NCT07887672 · Kite, A Gilead Company
2027-01 – 2042-02 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04071457 · SWOG Cancer Research Network
2019-08-13 – 2040-07-01 · Multiple Myeloma
What this study did
NCT06187441 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-05-14 – 2037-12 · Multiple Myeloma
What this study did
NCT07649525 · University of Leeds
2026-07-03 – 2037-06 · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
What this study did
NCT06932562 · European Myeloma Network B.V.
2025-12-23 – 2036-12 · Multiple Myeloma
What this study did
NCT06918002 · Intergroupe Francophone du Myelome
2025-07-09 – 2036-05 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07671287 · University of Heidelberg Medical Center
2026-06-30 – 2033-01-30 · Multiple Myeloma
What this study did
NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-03-12 – 2032-06-22 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05561387 · SWOG Cancer Research Network
2023-10-12 – 2031-05-30 · Plasma Cell Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03937635 · ECOG-ACRIN Cancer Research Group
2019-09-16 – 2029-12-31 · Smoldering Plasma Cell Myeloma
What this study did
NCT03710603 · Stichting European Myeloma Network
2018-12-14 – 2029-11 · Multiple Myeloma
What this study did
A Study of Daratumumabactive not recruiting
NCT05438043 · Janssen Research & Development, LLC
2022-12-15 – 2029-01-31 · Multiple Myeloma
What this study did
NCT04566328 · ECOG-ACRIN Cancer Research Group
2021-02-24 – 2027-12-31 · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
What this study did
NCT06296121 · Biocad
2023-12-21 – 2026-07 · Multiple Myeloma
What this study did
NCT03836014 · Assistance Publique - Hôpitaux de Paris
2019-07-25 – 2026-07 · Multiple Myeloma in Relapse
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT04288765 · Grupo Cooperativo de Hemopatías Malignas
2020-03-01 – 2025-02-28 · Multiple Myeloma
What this study did
NCT03180736 · Stichting European Myeloma Network
2017-06-14 – 2024-11-30 · Multiple Myeloma
What this study did
NCT02252172 · Janssen Research & Development, LLC
2015-02-16 – 2024-10-02 · Multiple Myeloma
What this study did
NCT03234972 · Janssen Research & Development, LLC
2017-11-30 – 2024-02-27 · Multiple Myeloma
What this study did
NCT03277105 · Janssen Research & Development, LLC
2017-10-27 – 2024-01-12 · Multiple Myeloma
What this study did
NCT02541383 · Intergroupe Francophone du Myelome
2015-09 – 2023-09-01 · Multiple Myeloma
What this study did
NCT03158688 · Amgen
2017-06-13 – 2022-04-15 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03792620 · Grupo de Estudos Multicentricos em Onco-Hematologia
2018-11-20 – 2022-04 · Multiple Myeloma Stage I
What this study did
Other / comorbidity
NCT06867991 · The First People's Hospital of Changzhou
2024-11-08 – 2027-11-08 · Anti-N-Methyl-D-Aspartate Receptor Encephalitis
What this study did
Phase 2/3 (7)
Multiple Myeloma
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
NCT04513639 · Oslo University Hospital
2020-08-27 – 2032-06-01 · Multiple Myeloma
What this study did
NCT02419118 · Vejle Hospital
2015-01 – 2015-10-01 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07072585 · Children's Oncology Group
2026-08-28 – 2035-09-01 · Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT05403138 · Tianjin Medical University General Hospital
2022-11-01 – 2025-12-01 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
What this study did
Phase 2 (173)
AL Amyloidosis
NCT07110844 · Rajshekhar Chakraborty, MD
2025-11-07 – 2033-10 · Amyloid Light-chain Amyloidosis
What this study did
NCT05898646 · Mayo Clinic
2023-09-06 – 2031-11-30 · AL Amyloidosis
What this study did
NCT07335887 · Peking University People's Hospital
2026-02-10 – 2028-08-31 · AL Amyloidosis (AL), t(11;14) Positive
What this study did
NCT04270175 · Weill Medical College of Cornell University
2021-04-14 – 2028-01 · Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
What this study did
NCT06629818 · Peking Union Medical College Hospital
2024-10-15 – 2027-03-14 · Light Chain (AL) Amyloidosis
What this study did
NCT05250973 · Janssen Research & Development, LLC
2022-03-01 – 2026-11-12 · Amyloidosis
What this study did
NCT04131309 · Stichting European Myeloma Network
2019-09-23 – 2025-01-27 · Light Chain (AL) Amyloidosis, Stage 3B
What this study did
NCT04895917 · Fondazione IRCCS Policlinico San Matteo di Pavia
2021-06-23 – 2025-01-15 · AL Amyloidosis
What this study did
NCT04474938 · Peking Union Medical College Hospital
2021-05-24 – 2024-03 · Amyloidosis; Systemic
What this study did
NCT04304144 · Alexion Pharmaceuticals, Inc.
2020-03-18 – 2023-11-14 · AL Amyloidosis
What this study did
NCT02816476 · University Hospital, Limoges
2016-09 – 2020-10 · Amyloidosis
What this study did
Multiple Myeloma
NCT07247097 · Massachusetts General Hospital
2026-08-01 – 2035-12-01 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT07107529 · European Myeloma Network B.V.
2025-12-12 – 2034-02 · Multiple Myeloma (MM)
What this study did
NCT06974786 · SCRI Development Innovations, LLC
2025-08-08 – 2033-04 · Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
What this study did
NCT04933539 · National Cancer Institute (NCI)
2022-10-31 – 2032-10-31 · Multiple Myeloma
What this study did
NCT06574126 · PETHEMA Foundation
2024-09-30 – 2032-09-30 · High Risk Smoldering Multiple Myeloma
What this study did
NCT05572229 · University Hospital, Lille
2023-12-21 – 2032-09 · Multiple Myeloma
What this study did
NCT07029776 · University of Arkansas
2027-03-01 – 2032-04-01 · Multiple Myeloma (MM)
What this study did
NCT04656951 · University of Cologne
2021-06-01 – 2031-12 · Multiple Myeloma
What this study did
NCT03289299 · International Myeloma Foundation
2018-05-25 – 2031-11-15 · Smoldering Multiple Myeloma
What this study did
NCT07764861 · Innovent Biologics (Suzhou) Co. Ltd.
2026-08-15 – 2031-06-30 · Multiple Myeloma
What this study did
NCT07830485 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-15 – 2031-04-30 · Multiple Myeloma
What this study did
NCT05896228 · Benjamin T Diamond, MD
2024-02-20 – 2031-03-01 · Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
DARA RVD For High Risk SMMactive not recruiting
NCT04775550 · Omar Nadeem, MD
2021-03-08 – 2030-12-08 · High-risk Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT06353022 · Nantes University Hospital
2024-06-26 – 2030-06-26 · Multiple Myeloma
What this study did
NCT07045909 · PETHEMA Foundation
2025-06-30 – 2030-03-31 · De Novo Multiple Myeloma, Anitocabtagene Autoleucel
What this study did
NCT06100237 · Carl Ola Landgren, MD, PhD
2023-12-04 – 2029-12-31 · Multiple Myeloma
What this study did
NCT05527340 · PETHEMA Foundation
2022-12-15 – 2029-12 · Multiple Myeloma
What this study did
NCT05231629 · University of Alabama at Birmingham
2023-12-13 – 2029-12 · Multiple Myeloma
What this study did
NCT05695508 · University of Heidelberg Medical Center
2022-12-01 – 2029-09-15 · Multiple Myeloma
What this study did
NCT05849610 · PETHEMA Foundation
2023-09-21 – 2029-07 · High-Risk de Novo Multiple Myeloma
What this study did
NCT07891923 · Tata Memorial Centre
2025-10-28 – 2029-05-05 · Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT06348147 · UNC Lineberger Comprehensive Cancer Center
2026-07 – 2029-05 · Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
What this study did
NCT07485647 · Eden Biltibo
2026-04-20 – 2029-04 · Multiple Myeloma
What this study did
NCT06107738 · Barbara Ann Karmanos Cancer Institute
2023-12-21 – 2028-12-31 · Multiple Myeloma
What this study did
NCT07638683 · Shanghai Zhongshan Hospital
2026-05-22 – 2028-12-30 · Multiple Myeloma, AL Amyloidosis
What this study did
NCT06505369 · North Estonia Medical Centre
2024-06-19 – 2028-10 · Multiple Myeloma
What this study did
NCT03004287 · University of Arkansas
2017-07-01 – 2028-10 · Multiple Myeloma
What this study did
NCT05497804 · Mayo Clinic
2022-09-22 – 2028-09-04 · ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
What this study did
NCT04133636 · Janssen Research & Development, LLC
2019-11-07 – 2028-08-25 · Multiple Myeloma
What this study did
NCT07018050 · Qilu Pharmaceutical Co., Ltd.
2025-09-12 – 2028-07 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04176718 · Andrew Yee, MD
2020-05-18 – 2028-05 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
What this study did
NCT03606577 · Nantes University Hospital
2019-07-30 – 2028-04-18 · Multiple Myeloma
What this study did
NCT04661137 · Hackensack Meridian Health
2021-03-16 – 2028-02 · Multiple Myeloma
What this study did
NCT06827860 · Larysa Sanchez
2025-11-18 – 2028-01 · Multiple Myeloma in Relapse
What this study did
NCT04756401 · Academic and Community Cancer Research United
2022-12-08 – 2027-12-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
Phase 1/2 (41)
AL Amyloidosis
NCT05486481 · Alfred Chung, MD
2024-01-08 – 2028-12-31 · AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
What this study did
NCT02841033 · Boston Medical Center
2017-03-20 – 2020-07-17 · AL Amyloidosis
What this study did
Multiple Myeloma
NCT06785415 · Mayo Clinic
2025-03-18 – 2031-04-01 · Recurrent Multiple Myeloma
What this study did
NCT07681596 · AstraZeneca
2026-07-27 – 2031-03-06 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT06119685 · Indapta Therapeutics, INC.
2023-10-25 – 2029-12-31 · NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT07099391 · Memorial Sloan Kettering Cancer Center
2025-07-24 – 2029-07-24 · Multiple Myeloma
What this study did
NCT05392946 · Mayo Clinic
2022-08-11 – 2028-09-29 · Plasma Cell Myeloma
What this study did
NCT05434689 · University of Alabama at Birmingham
2023-01-18 – 2028-08 · Multiple Myeloma
What this study did
NCT02773030 · Celgene
2016-10-14 – 2028-07-28 · Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT05581875 · Hellenic Society of Hematology
2022-10-20 – 2026-10-31 · Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
What this study did
NCT05280275 · Hellenic Society of Hematology
2022-04-13 – 2026-03-15 · Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05408026 · Alliance Foundation Trials, LLC.
2022-10-01 – 2026-02 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT05857982 · Second Affiliated Hospital of Soochow University
2023-05-20 – 2025-12-31 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT01665794 · University of Chicago
2012-08-13 – 2025-11-14 · Multiple Myeloma
What this study did
NCT06055075 · Hoffmann-La Roche
2023-12-08 – 2025-07-08 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT01615029 · Janssen Research & Development, LLC
2012-06-26 – 2024-10-23 · Multiple Myeloma
What this study did
NCT01592370 · Bristol-Myers Squibb
2012-08-02 – 2024-07-09 · Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
What this study did
NCT05590377 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-23 – 2024-05-22 · Multiple Myeloma
What this study did
NCT04776018 · Takeda
2021-04-20 – 2023-11-09 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT03481556 · Oncopeptides AB
2018-04-12 – 2022-02-02 · Multiple Myeloma
What this study did
NCT03701321 · National Cancer Institute (NCI)
2019-01-25 – 2020-05-28 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT03665155 · Memorial Sloan Kettering Cancer Center
2018-09-05 – 2020-04-20 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07075510 · University of Maryland, Baltimore
2025-10-23 – 2032-10-01 · Plasma Cell Disorder
What this study did
NCT07110662 · Hospices Civils de Lyon
2025-10-29 – 2029-04-29 · Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
What this study did
NCT07287228 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-17 – 2028-12-31 · Aplastic Anemia, Refractory, Relapse
What this study did
NCT05671757 · National Institute of Allergy and Infectious Diseases (NIAID)
2023-05-26 – 2028-05-05 · Autoimmune Disorders
What this study did
NCT04922723 · West Virginia University
2022-10-03 – 2026-12 · Glioblastoma
What this study did
NCT04827979 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-11-01 – 2026-09-10 · Highly Sensitized Prospective Kidney Transplant Recipients
What this study did
NCT05205252 · Epizyme, Inc.
2021-12-22 – 2023-07-05 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
What this study did
NCT04204980 · Assistance Publique - Hôpitaux de Paris
2020-02-18 – 2023-06-01 · Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
What this study did
NCT02488759 · Bristol-Myers Squibb
2015-10-13 – 2022-10-24 · Various Advanced Cancer
What this study did
NCT03537599 · Sumithira Vasu
2020-01-10 – 2022-02-03 · Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
What this study did
NCT03023423 · Janssen Research & Development, LLC
2016-12-23 – 2019-09-26 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 1 (59)
AL Amyloidosis
NCT03283917 · M.D. Anderson Cancer Center
2018-02-07 – 2026-06-17 · Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
What this study did
Multiple Myeloma
NCT06622005 · Roswell Park Cancer Institute
2025-04-10 – 2030-04-10 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT07221032 · Medical College of Wisconsin
2026-08-05 – 2030-03 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT06768489 · Janssen Research & Development, LLC
2024-12-04 – 2029-06-29 · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT04910568 · Genentech, Inc.
2021-07-26 – 2028-12-21 · Multiple Myeloma
What this study did
NCT06398457 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-09-19 – 2028-03 · Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
What this study did
NCT07082270 · Roswell Park Cancer Institute
2026-04-01 – 2028-02-01 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT04108195 · Janssen Research & Development, LLC
2020-02-21 – 2027-12-31 · Multiple Myeloma
What this study did
NCT06142396 · Augusta University
2024-11-01 – 2027-11-01 · Multiple Myeloma, Renal Failure
What this study did
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT05363111 · City of Hope Medical Center
2022-11-22 – 2027-03-23 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT05139225 · Memorial Sloan Kettering Cancer Center
2021-10-28 – 2026-07-01 · Multiple Myeloma
What this study did
NCT04667663 · Cancer Trials Ireland
2021-12-08 – 2026-04-30 · Multiple Myeloma
What this study did
NCT05308654 · AbbVie
2022-05-17 – 2025-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05182073 · Fate Therapeutics
2021-11-10 – 2024-10-18 · Multiple Myeloma, Myeloma
What this study did
NCT05243342 · Genentech, Inc.
2022-04-28 – 2024-07-10 · Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT04892264 · Mayo Clinic
2021-06-03 – 2024-03-18 · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04121260 · Janssen Research & Development, LLC
2019-12-25 – 2023-10-13 · Multiple Myeloma
What this study did
NCT04614636 · Fate Therapeutics
2020-10-17 – 2023-08-08 · Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
What this study did
NCT05641324 · Anaveon AG
2023-02-10 – 2023-07-12 · Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
What this study did
NCT03311828 · City of Hope Medical Center
2018-02-21 – 2023-06-05 · Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
What this study did
NCT04136756 · Nektar Therapeutics
2019-10-07 – 2023-04-24 · Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
What this study did
NCT02519452 · Janssen Research & Development, LLC
2015-10-22 – 2023-04-03 · Multiple Myeloma
What this study did
NCT03242889 · Janssen Pharmaceutical K.K.
2017-08-10 – 2023-02-10 · Multiple Myeloma
What this study did
NCT04956302 · Abdullah Khan
2021-09-27 – 2022-06-16 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04280328 · Corvus Pharmaceuticals, Inc.
2020-02-20 – 2022-03-01 · Multiple Myeloma
What this study did
NCT02955810 · National University of Ireland, Galway, Ireland
2016-11 – 2020-11 · Multiple Myeloma
What this study did
NCT02852837 · Janssen Research & Development, LLC
2016-09-26 – 2019-12-13 · Multiple Myeloma
What this study did
NCT03068351 · Hoffmann-La Roche
2017-06-26 – 2019-08-01 · Multiple Myeloma
What this study did
NCT02497378 · Janssen Pharmaceutical K.K.
2015-07-10 – 2018-03-06 · Multiple Myeloma
What this study did
NCT02116569 · Janssen Pharmaceutical K.K.
2014-04 – 2015-09 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07513129 · M.D. Anderson Cancer Center
2026-06-05 – 2031-12-31 · T-cell Acute Lymphoblastic Leukemia, Lymphoma
What this study did
NCT04139304 · AIDS Malignancy Consortium
2021-05-24 – 2030-07 · Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
What this study did
NCT04972942 · New York Medical College
2023-05-22 – 2028-09 · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
What this study did
NCT05749276 · Nantes University Hospital
2025-02-06 – 2028-08-06 · Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
What this study did
NCT07026604 · Beijing Tiantan Hospital
2025-07-01 – 2026-11-01 · Cavernous Malformation, Cerebral
What this study did
NCT03447808 · Jennifer Woyach
2018-08-16 – 2026-05-26 · Chronic Lymphocytic Leukemia
What this study did
NCT03473730 · M.D. Anderson Cancer Center
2018-05-29 – 2025-01-27 · Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
What this study did
Phase 4 (9)
Multiple Myeloma
NCT03829371 · University of Turin, Italy
2019-01-03 – 2030-01-03 · Multiple Myeloma
What this study did
NCT07191379 · Odense University Hospital
2026-11-01 – 2028-01-01 · Multiple Myeloma in Relapse
What this study did
NCT06409702 · The First Affiliated Hospital of Soochow University
2024-06-12 – 2027-12-31 · Newly Diagnosed, High Risk, MRD, Multiple Myeloma
What this study did
NCT05511428 · Thomas Jefferson University
2022-11-08 – 2024-05-22 · Plasma Cell Myeloma
What this study did
Other / comorbidity
NCT05849740 · Institute of Hematology & Blood Diseases Hospital, China
2023-05-22 – 2027-10-31 · Acquired Hemophilia
What this study did
NCT07274462 · University Hospital, Martin
2025-11-01 – 2027-09-30 · Microvascular Inflammation - MVI in Kindey Transplant Recipients
What this study did
NCT07788456 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-22 – 2027-06-30 · ITP - Immune Thrombocytopenia
What this study did
NCT05888870 · Institute of Hematology & Blood Diseases Hospital, China
2023-11-22 – 2026-12-01 · Hemophilia A With Inhibitor
What this study did
Early phase / not applicable (9)
AL Amyloidosis
NCT06192979 · Jin Lu, MD
2024-01-05 – 2027-03-31 · Amyloidosis; Systemic, AL Amyloidosis
What this study did
NCT06376214 · Nanjing University School of Medicine
2023-01-01 – 2026-12-31 · Light Chain (AL) Amyloidosis
What this study did
Multiple Myeloma
NCT06697483 · Peking University People's Hospital
2024-12-01 – 2027-12-31 · Multiple Myeloma
What this study did
NCT07721350 · Hospices Civils de Lyon
2026-10 – 2027-05 · Multiple Myeloma or Amyloidosis
What this study did
NCT07015021 · The First Affiliated Hospital of Soochow University
2025-06-01 – 2026-09-30 · Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
What this study did
NCT05088330 · The First Affiliated Hospital of Soochow University
2021-12-01 – 2024-12-31 · Newly Diagnosed Multiple Myeloma
What this study did
Other / comorbidity
NCT07081126 · University Hospital, Martin
2025-07-01 – 2026-12-31 · Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
What this study did
NCT05913596 · First Affiliated Hospital of Zhejiang University
2023-05-23 – 2024-08-30 · Antibody-mediated Rejection, Kidney Tranplant
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (25)
AL Amyloidosis
NCT07901725 · Regeneron Pharmaceuticals
2026-12-18 – 2035-07-25 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
What this study did
Multiple Myeloma
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT07393282 · Regeneron Pharmaceuticals
2026-05-21 – 2033-07-27 · High Risk Smoldering Multiple Myeloma (HR-SMM)
What this study did
NCT07555938 · Hoffmann-La Roche
2026-06-23 – 2033-01-31 · Multiple Myeloma
What this study did
NCT06182774 · Canadian Cancer Trials Group
2024-04-10 – 2032-07-31 · Multiple Myeloma
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT06464991 · Nanjing IASO Biotechnology Co., Ltd.
2024-03-27 – 2030-12 · Multiple Myeloma
What this study did
NCT07910903 · Keymed Biosciences Co.Ltd
2026-12 – 2030-11 · Multiple Myeloma (MM)
What this study did
NCT07933432 · Qilu Pharmaceutical Co., Ltd.
2026-12-30 – 2030-05-21 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07452198 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.
2026-03-09 – 2030-03 · Multiple Myeloma
What this study did
NCT07623798 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-11 – 2029-12-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT06742138 · Qilu Pharmaceutical Co., Ltd.
2025-01 – 2028-12 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Phase 2/3 (1)
Multiple Myeloma
NCT07428369 · Regeneron Pharmaceuticals
2026-06-05 – 2038-05-21 · Multiple Myeloma (MM)
What this study did
Phase 2 (1)
Multiple Myeloma
NCT06931704 · Nantes University Hospital
2025-07-09 – 2031-11-30 · Multiple Myeloma
What this study did
Phase 1/2 (3)
AL Amyloidosis
NCT05451771 · Columbia University
2022-10-26 – 2027-09 · AL Amyloidosis
What this study did
Multiple Myeloma
NCT04824794 · Genmab
2021-03-09 – 2025-07-31 · Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
What this study did
NCT03837509 · Incyte Corporation
2019-09-25 – 2022-04-05 · Relapsed or Refractory Multiple Myeloma
What this study did
Phase 1 (5)
Multiple Myeloma
NCT07400744 · Qilu Pharmaceutical Co., Ltd.
2026-03 – 2026-10 · Multiple Myeloma
What this study did
NCT05679258 · Shanghai Henlius Biotech
2023-01-31 – 2024-06-28 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06371534 · Qilu Pharmaceutical Co., Ltd.
2024-04-12 – 2025-04 · Tumor
What this study did
NCT05974969 · Biocad
2023-05-17 – 2023-08-15 · Healthy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Multiple Myeloma
NCT04649060 · Oncopeptides AB
2020-12-21 – 2022-02-07 · Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Daratumumab: this drugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Anselamimab (Amlypave)Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Mezagitamab
Phase 3(overall)
Monoclonal antibodyCD38
Weak signal(overall)
No reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
BirtamimabDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(130 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Daratumumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04922723 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 2Cardiac TransplantEnrolling by invitation
Est. primary completion 2026-12 · NCT05300451 · CT.gov ↗
What to watch
Phase 4Hemophilia A With InhibitorRecruiting
Est. primary completion 2026-12-01 · NCT05888870 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07764861 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06697483 · CT.gov ↗
What to watch
2027 (46)
January 2027 (3)
Phase 2AL AmyloidosisActive not recruiting
Est. primary completion 2027-01 · NCT04270175 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-01 · NCT06827860 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (6)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-03 · NCT07362199 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Phase 4Microvascular Inflammation - MVI in Kindey Transplant RecipientsActive not recruiting
Est. primary completion 2027-03-01 · NCT07274462 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-03-08 · NCT06952478 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-03-23 · NCT05363111 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04108195 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-10 · NCT06622005 · CT.gov ↗
What to watch
Phase 4Acquired HemophiliaRecruiting
Est. primary completion 2027-04-30 · NCT05849740 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05 · NCT04176718 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaNot yet recruiting
Est. primary completion 2027-05 · NCT07721350 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-05-17 · NCT03346135 · CT.gov ↗
What to watch
Phase 4ITP - Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-05-30 · NCT07788456 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06015724 · CT.gov ↗
What to watch
Phase 2Kidney Failure, Paraproteinemias, GlomerulonephritisRecruiting
Est. primary completion 2027-06 · NCT06889948 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT05572229 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2027-06-29 · NCT07191379 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT05289687 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-01 · NCT04124497 · CT.gov ↗
What to watch
Phase 2Plasmablastic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05455320 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT04497961 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic LymphomaRecruiting
Est. primary completion 2027-09 · NCT04972942 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-09 · NCT06398457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-08 · NCT04635189 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
November 2027 (5)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-11 · NCT07297563 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-11-01 · NCT06142396 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Phase 1/2Aplastic Anemia, Refractory, RelapseRecruiting
Est. primary completion 2027-12-31 · NCT07287228 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT06107738 · CT.gov ↗
What to watch
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2027-12-31 · NCT07335887 · CT.gov ↗
What to watch
Phase 2Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)Active not recruiting
Est. primary completion 2027-12-31 · NCT07902609 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
2028 (22)
February 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruiting
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02-28 · NCT06948084 · CT.gov ↗
What to watch
March 2028 (5)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT07221032 · CT.gov ↗
What to watch
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-03 · NCT07362238 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗
What to watch
Phase 1/2Autoimmune DisordersRecruiting
Est. primary completion 2028-05-05 · NCT05671757 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-07 · NCT07742215 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-07-30 · NCT07638683 · CT.gov ↗
What to watch
August 2028 (3)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2028-08 · NCT05434689 · CT.gov ↗
What to watch
Phase 2Proliferative Glomerulonephritis With Monoclonal IgG DepositsActive not recruiting
Est. primary completion 2028-08 · NCT05654506 · CT.gov ↗
What to watch
Phase 1Adult Patients With Adverse Risk Acute Myeloblastic LeukemiaRecruiting
Est. primary completion 2028-08-06 · NCT05749276 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-09 · NCT05231629 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)Not yet recruiting
Est. primary completion 2028-10-29 · NCT07110662 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-11 · NCT07234019 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT06100237 · CT.gov ↗
What to watch
2029 (19)
January 2029 (5)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 2Primary Plasma Cell LeukemiaRecruiting
Est. primary completion 2029-01-05 · NCT06636552 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-03-01 · NCT05896228 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT07107529 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-04-15 · NCT07830485 · CT.gov ↗
What to watch
May 2029 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-05-05 · NCT07891923 · CT.gov ↗
What to watch
Phase 1Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeRecruiting
Est. primary completion 2029-05-19 · NCT06287944 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
July 2029 (2)
Phase 1Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2029-07 · NCT04139304 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-07-24 · NCT07099391 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2T-Lymphocytic Leukemia, AcuteActive not recruiting
Est. primary completion 2029-10 · NCT06253637 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2029-11-30 · NCT05898646 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2029-12 · NCT05527340 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3AL AmyloidosisRecruiting
Est. primary completion 2030-07-29 · NCT06022939 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-09-04 · NCT07665450 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1/2Plasma Cell DisorderRecruiting
Est. primary completion 2030-10-01 · NCT07075510 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗
What to watch
December 2030 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
2031 (9)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch
March 2031 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-03-06 · NCT07681596 · CT.gov ↗
What to watch
April 2031 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2031-04-01 · NCT06785415 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
May 2031 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2031-06-01 · NCT04513639 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2AL AmyloidosisRecruiting
Est. primary completion 2031-10 · NCT07110844 · CT.gov ↗
What to watch
2032 (4)
September 2032 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2032-09 · NCT04071457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-09-30 · NCT06574126 · CT.gov ↗
What to watch
November 2032 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
2033 (4)
June 2033 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
Phase 2Lymphoma, Primary EffusionRecruiting
Est. primary completion 2034-08-01 · NCT05907759 · CT.gov ↗
What to watch
2035 (2)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (2)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch
2037 (1)
January 2037 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2037-01-11 · NCT07903272 · CT.gov ↗
What to watch
2041 (1)
March 2041 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2041-03 · NCT07095452 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch
2044 (1)
September 2044 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2044-09 · NCT06358638 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 March 2026ApprovalCHMP approves self/caregiver administration of DARZALEX SC label update
EU, EMA · Source ↗
5 March 2026ApprovalFDA approves TECVAYLI plus DARZALEX FASPRO for RRMM
US, FDA · Source ↗
27 January 2026ApprovalFDA approves DARZALEX FASPRO D-VRd for transplant-ineligible newly diagnosed multiple myeloma
US, FDA · Source ↗
9 December 2025Filing submittedsBLA submitted for TECVAYLI plus DARZALEX FASPRO in RRMM
US, FDA · Source ↗
6 November 2025ApprovalFDA approves DARZALEX FASPRO for high-risk smoldering multiple myeloma
US, FDA · Source ↗
8 December 2024Topline resultAQUILA (NCT03301220) Phase 3 met its primary endpoint
Johnson & Johnson · Source ↗